memo - Magazine of European Medical Oncology

, Volume 6, Issue 4, pp 262–266 | Cite as

Targeted delivery of anticancer agents using antibodies as vectors

  • Maria Toloudi
  • Ioannis PapasotiriouEmail author
short review


An important step in cancer drug research and development is to generate molecules and agents with better outcomes for inhibition of cancer progression. To date, classic cytotoxic chemotherapy is one of the most frequent methods of treatment. Cytotoxic agents currently used frequently have severe side effects. Thus, clinicians are forced to reduce the recommended dosage, or even avoid the extreme usage of these agents because they are nonselective and are distributed to healthy cells as well as cancer cells. Antibody drug conjugates (ADCs) are a new generation of drugs that consist of three parts: a monoclonal antibody (monoclonal antibodies), a small molecule, and a linker between the two. The use of this structure in research pipelines and recently in clinical practice is likely to achieve more precise and selective distribution and delivery of the cytotoxic agents to cancer cells. This review analyzes the structure of ADCs and the advantages of targeted chemotherapeutics. Possible methods of improvement are also discussed.


Immunoconjugate Cytotoxin Heterogeneous mixture Linker conjunction Targeted drug delivery 


Conflict of interest

The authors declare that there are no conflicts of interest in relation to this article.


  1. 1.
    Ren L, Du X, Hu M, Yan C, Liang T, Li Q. Design, synthesis and antitumor activity of novel 4-methyl-(3’S,4’S)-cis-khellactone derivatives. Molecules. 2013;18(4):4158–69.PubMedCrossRefGoogle Scholar
  2. 2.
    El-Gohary NS, Shaaban MI. Synthesis, antimicrobial, antiquorum-sensing, antitumor and cytotoxic activities of new series of fused [1,3,4]thiadiazoles. Eur J Med Chem. 2013 May;63:185–95.PubMedCrossRefGoogle Scholar
  3. 3.
    Radwan AA, Alanazi FK, Al-Dhfyan A. Synthesis, and docking studies of some fused-quinazolines and quinazolines carrying biological active isatin moiety as cell-cycle inhibitors of breast cancer cell lines. Drug Res (Stuttg). 2013 Mar;63(3):129–36.CrossRefGoogle Scholar
  4. 4.
    Gellibert F, Fouchet MH, Nguyen VL, Wang R, Krysa G, de Gouville AC, et al. Design of novel quinazoline derivatives and related analogues as potent and selective ALK5 inhibitors. Bioorg Med Chem Lett. 2009 Apr 15;19(8):2277–81.PubMedCrossRefGoogle Scholar
  5. 5.
    Karpas A, Dremucheva A, Czepulkowski BH. A human myeloma cell line suitable for the generation of human monoclonal antibodies. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1799–804.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12:14.PubMedGoogle Scholar
  7. 7.
    Strebhardt K, Ullrich A. Paul Ehrlich’s magic bullet concept: 100 years of progress. Nat Rev Cancer. 2008 Jun;8(6):473–80.PubMedCrossRefGoogle Scholar
  8. 8.
    Mathe G, Tran Ba LO, Bernard J. [Effect on mouse leukemia 1210 of a combination by diazo-reaction of amethopterin and gamma-globulins from hamsters inoculated with such leukemia by heterografts]. C R Hebd Seances Acad Sci. 1958 Mar 10;246(10):1626–8.PubMedGoogle Scholar
  9. 9.
    Vlachakis D, Kossida S. Antibody drug conjugate bioinformatics: drug delivery through the letterbox. Comput Math Methods Med. 2013;2013:282398.PubMedGoogle Scholar
  10. 10.
    Burris HA. Developments in the use of antibody-drug conjugates. Am Soc Clin Oncol Educ Book. 2013;2013:99–102.CrossRefGoogle Scholar
  11. 11.
    Firer MA, Gellerman G. Targeted drug delivery for cancer therapy: the other side of antibodies. J Hematol Oncol. 2012;5:70.PubMedCentralPubMedCrossRefGoogle Scholar
  12. 12.
    Mathur R, Weiner GJ. Picking the optimal target for antibody-drug conjugates. Am Soc Clin Oncol Educ Book. 2013;2013:103–7.CrossRefGoogle Scholar
  13. 13.
    Litzow MR. Monoclonal antibody-based therapies in the treatment of acute lymphoblastic leukemia. Am Soc Clin Oncol Educ Book. 2013;2013:294–9.CrossRefGoogle Scholar
  14. 14.
    Sapra P, Shor B. Monoclonal antibody-based therapies in cancer: advances and challenges. Pharmacol Ther. 2013 Jun;138(3):452–69.PubMedCrossRefGoogle Scholar
  15. 15.
    Cianfriglia M. The biology of MDR1-P-glycoprotein (MDR1-Pgp) in designing functional antibody drug conjugates (ADCs): the experience of gemtuzumab ozogamicin. Ann Ist Super Sanita. 2013;49(2):150–68.PubMedGoogle Scholar
  16. 16.
    Acchione M, Kwon H, Jochheim CM, Atkins WM. Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibodydrug conjugates. MAbs. 2012 May–Jun;4(3):362–72.PubMedCentralPubMedCrossRefGoogle Scholar
  17. 17.
    Feld J, Barta SK, Schinke C, Braunschweig I, Zhou Y, Verma AK. Linked-in: design and efficacy of antibody drug conjugates in oncology. Oncotarget. 2013 Mar;4(3):397–412.PubMedGoogle Scholar
  18. 18.
    Leriche G, Chisholm L, Wagner A. Cleavable linkers in chemical biology. Bioorg Med Chem. 2012 Jan 15;20(2):571–82.PubMedCrossRefGoogle Scholar
  19. 19.
    Kaur S, Xu K, Saad OM, Dere RC, Carrasco-Triguero M. Bioanalytical assay strategies for the development of antibody-drug conjugate biotherapeutics. Bioanalysis. 2013 Jan;5(2):201–26.PubMedCrossRefGoogle Scholar
  20. 20.
    Sapra P, Damelin M, Dijoseph J, Marquette K, Geles KG, Golas J, et al. Long-term tumor regression induced by an antibody-drug conjugate that targets 5T4, an oncofetal antigen expressed on tumor-initiating cells. Mol Cancer Ther. 2013 Jan;12(1):38–47.PubMedCrossRefGoogle Scholar
  21. 21.
    Sun Y, Yu F, Sun BW. Antibody-drug conjugates as targeted cancer therapeutics. Yao Xue Xue Bao. 2009 Sep;44(9):943–52.PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2013

Authors and Affiliations

  1. 1.Research Genetic Cancer Centre Ltd (R.G.C.C. Ltd)FilotasGreece

Personalised recommendations